Recent Finacing
Recent Raise
BeneVir develops NYU‑licensed T‑Stealth oncolytic herpes viruses engineered to selectively replicate in and lyse cancer cells, evade immune clearance, and remodel antigen presentation to activate anti‑tumor T cells.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor